한국지질동맥경화학회 학술대회

The cardio-renal-metabolic vicious cycle: choosing the suitable statin for complex risk profiles

Lowest is the best: reduction of LDL-C level and CV risk in ASCVD patients

Upfront lipid-lowering combination therapy in very high-risk patients: not a choice, a necessity

TBD

Meeting an unmet need: low-dose atorvastatin for Korean patients

Exploring the genetic landscape of CVD and diabetes: finding and future implication

Multi-omics and multi-trait analysis of metabolic disease

Recent progress in gene-targeting therapy for familial hypercholesterolemia

Metabolic disease promotes deoxyceramide accumulation in immune cells altering cytokine production

The role of digital health technology in managing atherosclerosis

Impact of lipid-lowering therapy on aortic aneurysm progression and cardiovascular outcomes

Remnant cholesterol as a residual risk in ASCVD patients under statin-based lipid-lowering therapy

Association between remnant cholesterol and sarcopenia: implications on muscle health

Targeting remnant cholesterol in the era of precision lipid management

2024 KSoLA consensus on secondary dyslipidemia

Understanding the progression of obesity-induced organ damage: Insights from the EAS staging system

Sex-specific gaps in lipid management and ASCVD

Advances in lipid-lowering therapy: shaping the future of cardiovascular prevention

Integrating ChatGPT into medical and clinical research workflows

Integrated management of hypertension and dyslipidemia for cardiovascular disease prevention

A new "standard" in dyslipidemia treatment

Recent trends and clinical evidence for optimizing lipid management

Closing the LDL-C gap in ASCVD: the role of siRNA therapy

Vascular tortuocity and atherosclerosis burden

Vessel wall enhancement and inflammation

Blood viscocity and intracranial atherosclerosis

Environmental pollution as a nontraditional risk factor for atherosclerotic cardiovascular disease: mechanisms and impacts

Health inequity as a nontraditional risk factor for ASCVD

Psychiatric disorders: an overlooked nontraditional risk factor in the development of atherosclerotic cardiovascular disease

Optimal LDL-C goals for secondary prevention in high-risk patients - a cardiologist’s perspective

Optimal LDL-C level for stroke prevention - insights from a neurologist’s perspective

Different LDL-C targets by duration of diabetes: what is the evidence? - an endocrinologist’s perspective

Multi-omics data integration from patients with carotid stenosis illuminates key molecular signatures of atherosclerotic instability

Bempedoic acid in real world practice, for whom?

Targeting APOC 3 for triglyceride management

ANGPTL3 and ANGPTL8 inhibition: novel strategies to combat atherogenic dyslipidemia

Triglyceride and HDL-C focus in Asian populations: rethinking priorities?

Combination lipid-lowering therapy: when statins alone are not enough

Ethnic differences in managing dyslipidemia: tailoring treatment strategies for Asian and Western populations

Biological and hormonal mechanisms linking sex and cardiometabolic risk

Sex and gender differences in risk assessment and biomarkers for cardiovascular disease

Do women and men respond differently to cardiometabolic therapies?

Glutamine homeostasis: an overlooked axis in cardiometabolic inflammation

Myeloid metabolism in the amplification and resolution of cardiac inflammation

Therapeutic promise of ANGPTL4 in cardiovascular inflammation